Coeptis Therapeutics, Inc. Stock OTC Markets
Equities
COEP
US19207C1045
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 12.08M 16.52M |
---|---|---|---|---|---|
Net income 2024 * | -26M -35.54M | Net income 2025 * | -35M -47.84M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
-0.38
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.46% |
Managers | Title | Age | Since |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 22-10-27 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 23-05-16 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 22-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 22-10-27 | |
Director/Board Member | 55 | 22-10-27 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 22-10-27 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |